Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 9/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MMP13 | P45452 | 6/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117443 | 0.94 | PTGER1 (0.51) | PTGER1MAPTNPC1RAB9AMMP13 | |
| SCHEMBL5119554 | 0.91 | PTGER1 (0.57) | PTGER1MAPTNPC1RAB9AMMP13 | |
| SCHEMBL5125098 | 0.91 | MMP13 (0.54) | PTGER1MAPTNPC1RAB9AMMP13 | |
| SCHEMBL4722380 | 0.89 | PTGER1 (0.75) | PTGER1MAPTNPC1RAB9AMMP13 | |
| SCHEMBL14098751 | 0.88 | PTGER1 (0.65) | PTGER1MMP13CYP1A2 | |
| SCHEMBL5125898 | 0.88 | MAPT (0.52) | PTGER1MAPTNPC1RAB9AMMP13 | |
| SCHEMBL5115859 | 0.86 | PTGER1 (0.78) | PTGER1CYP1A2 | |
| SCHEMBL4723594 | 0.86 | PTGER1 (0.56) | PTGER1MAPTNPC1RAB9AMMP13 | |
| SCHEMBL5130514 | 0.85 | MAPT (0.48) | PTGER1MAPTNPC1RAB9AMMP13 | |
| SCHEMBL5120611 | 0.84 | PTGER1 (0.49) | PTGER1MAPTNPC1RAB9AMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1874776-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006114274-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | PTGER1, PTGER2, PTGER4 | PTGER1 1/4885MAPT 4703/4885NPC1 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.